Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.

[1]  P. Ghislain,et al.  Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults , 2023, Advances in therapy.

[2]  K. Peris,et al.  Successful response of upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab. , 2023, Clinical and experimental dermatology.

[3]  A. Deodhar,et al.  Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis , 2023, RMD Open.

[4]  A. Costanzo,et al.  Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study , 2023, Dermatology and Therapy.

[5]  M. Schuttelaar,et al.  Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry , 2023, Contact dermatitis.

[6]  G. Fabbrocini,et al.  Efficacy and safety of upadacitinib in adult patients affected by moderate to severe atopic dermatitis: a 16-week real-life dual-centre experience. , 2022, Clinical and experimental dermatology.

[7]  G. Fabbrocini,et al.  Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study , 2022, Drugs in R&D.

[8]  K. Peris,et al.  Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis , 2022, Expert opinion on drug metabolism & toxicology.

[9]  J. Thyssen,et al.  Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis , 2022, JAMA dermatology.

[10]  K. Peris,et al.  Therapeutic Impact and Management of Persistent Head and Neck Atopic Dermatitis in Dupilumab-Treated Patients , 2021, Dermatology.

[11]  A. Costanzo,et al.  Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis , 2021, JAMA dermatology.

[12]  G. Argenziano,et al.  Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study , 2021, American Journal of Clinical Dermatology.

[13]  K. Peris,et al.  Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy , 2021, Dermatology.

[14]  C. Flohr,et al.  Systemic treatments in the management of atopic dermatitis: A systematic review and meta‐analysis , 2020, Allergy.

[15]  K. Peris,et al.  Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)* , 2020, The British journal of dermatology.

[16]  G. Dal Bello,et al.  Drug survival of dupilumab compared to cyclosporin in moderate‐to‐severe atopic dermatitis patients , 2020, Dermatologic therapy.

[17]  J. Silverberg,et al.  Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial. , 2019, Journal of Allergy and Clinical Immunology.

[18]  T. Bieber,et al.  Atopic dermatitis , 2018, Nature Reviews Disease Primers.

[19]  D. Margolis,et al.  Epidemiology of atopic dermatitis in adults: Results from an international survey , 2018, Allergy.

[20]  M. Cork,et al.  Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) , 2018, The British journal of dermatology.

[21]  E. Lopez-Gonzalez,et al.  Determinants of Under-Reporting of Adverse Drug Reactions , 2009, Drug safety.

[22]  L. Hazell,et al.  Under-Reporting of Adverse Drug Reactions , 2006, Drug safety.